TITAN BIOTECH LIMITED

AN ISO 9001:2015 CERTIFIED COMPANY

Office: 903-909. 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India
Telephone no.: 011-27355742, 71239900(44 Lines), CIN: L74999RJ1992PLC013387

November 05, 2026

To,
Corporate Services Department,
BSE Ltd.,
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai- 400001

BSE Scrip Code: 524717
ISIN: INE150C01029

Dear Sir,

Sub: Outcome of Meeting of the Board of Directors of Titan Biotech Limited (the Company) held on November 05, 2026

In terms of the requirements of Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circulars, as amended from time to time, this is to inform you that the Board of Directors at its meeting held today, i.e. Thursday, November 05, 2026, has, *inter- alia a*pproved the Unaudited Standalone and Consolidated financial results of the Company for the quarter and half year ended September 30, 2026 as reviewed by the Audit Committee and approved by the Board of Directors of the Company.

Please find enclosed, unaudited financial result (Standalone & Consolidated) along with the Limited Review Report issued by the statutory auditors of the Company for the quarter and half year ended September 30, 2026.

The meeting of Board of Directors commenced at **03:00 P.M. and concluded at 03:32 P.M**.

The above information will be available on the website of the company i.e www.titanbiotechltd.com and BSE Ltd i.e www.bseindia.com.

Request to kindly take this information on record and acknowledge.

For and on behalf of
Titan Biotech Limited

CHARANJIT SINGH
Digitally signed by CHARANJIT SINGH
Date: 2026.11.05 15:38:22 +05'30'

Charanjit Singh
Company Secretary & Compliance Officer
M.No A12726

TITAN BIOTECH LIMITED

Encl: As above

ANSK & ASSOCIATES
CHARTERED ACCOUNTANTS
Office : 705, B-08, GDITL Tower, Netaji Subhash Place Pitampura, New Delhi - 110034
Tel : 011-46010089

Independent Auditor's Review Report on Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

THE BOARD OF DIRECTORS
TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Titan Biotech Limited (the "Company"), for the quarter ended September 30, 2026, being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters,

and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A N S K & Associates
Chartered Accountants
Firm's Registration No. 026177N

KAPIL SINGHAL
Digitally signed by KAPIL SINGHAL
Date: 2026.11.05 15:08:09 +05'30'

(CA Kapil Singal)
Partner
M.No. 520205
Date: November 05, 2026
Place: New Delhi
UDIN: 26520205VGMPVV3634

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED ON 30TH SEPTEMBER, 2026

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	STANDALONE					
		QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	**INCOME**						
	Revenue from operations	7,646.25	5,916.66	5,435.47	13,562.91	10,085.11	20,619.03
	Other income	172.03	181.26	132.45	353.29	204.67	541.02
	Total income	**7,818.28**	**6,097.92**	**5,567.92**	**13,916.20**	**10,289.78**	**21,160.05**
2	**EXPENSES**						
	Cost of materials consumed	3,951.09	2,992.80	2,742.73	6,943.89	4,598.01	9,916.35
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	41.12	(203.91)	(137.86)	(162.79)	401.81	(296.82)
	Employee benefits expense	966.70	869.68	738.26	1,836.38	1,439.58	3,236.20
	Finance costs	27.97	19.88	22.41	47.85	41.93	91.39
	Depreciation and amortization expense	132.50	136.69	120.95	269.19	236.15	492.53
	Other expenses	1,186.30	1,009.36	1,159.57	2,195.66	1,839.23	3,902.95
	Total expenses	**6,305.68**	**4,824.50**	**4,646.06**	**11,130.18**	**8,556.71**	**17,342.60**
3	**Profit before exceptional items and tax (1-2)**	1,512.60	1,273.42	921.86	2,786.02	1,733.07	3,817.45
4	Exceptional items		-	-		-	-
5	**Profit before tax (3+4)**	1,512.60	1,273.42	921.86	2,786.02	1,733.07	3,817.45
6	Tax expense						
	(I) Current tax	379.76	321.79	231.55	701.55	423.83	988.74
	(II) Deferred tax	(0.25)	6.04	4.06	5.79	6.91	83.99
	(III) Earlier year taxes	0.02	-	-	0.02	-	-
	Total tax (I+II+III)	379.53	327.83	235.61	707.36	430.74	1,072.73
7	**Profit for the period (5-6)**	**1,133.07**	**945.59**	**686.25**	**2,078.66**	**1,302.33**	**2,744.72**
8	**Other comprehensive income**						
A	(i) Items that will not be reclasssified to profit or loss						
	(ia) Re-measurement gain on defined benefit plans	(3.04)	(3.05)	2.44	(6.09)	4.88	(12.19)
	(ii) Income tax on the above item	0.76	0.77	(0.62)	1.53	(1.23)	3.54
B	(i) Items that will be reclasssified to profit or loss			-		-	-
	(ii) Income tax on the above item			-		-	-
	Total other comprehensive income for the period (A+B) (net of taxes)	**(2.28)**	**(2.28)**	**1.82**	**(4.56)**	**3.65**	**(8.65)**
9	**Total comprehensive income for the period (7+8)**	**1,130.79**	**943.31**	**688.07**	**2,074.10**	**1,305.98**	**2,736.07**
10	Paid-up equity share capital (face value of Rs. 2/- each)	826.37	826.37	826.37	826.37	826.37	826.37
11	Other Equity						16,257.78
12	Earnings per equity share (face value of Rs.2/- each) not annualised						
	(1) Basic	2.74	2.29	8.30	5.03	15.76	6.64
	(2) Diluted	2.74	2.29	8.30	5.03	15.76	6.64

Notes:

1 The above unaudited standalone financial results for the quarter and six months ended on 30.09.2026 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on November 05, 2026.The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirments), 2015.The results for the quarter and six months ended on 30th Sept. 2026, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)

2 Previous period figures are regrouped/reclassified in line with the current period.

3 The Company has only one reportable busines segment.

4 The unaudited standalone financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").

5 Freight amount has been added in revenue from operations for the purpose of calculation of sales excluding GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director
DIN-00027448

Place : Delhi
Dated : 05.11.2026

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED ON 30TH SEPTEMBER, 2026

(Rs. IN LAKHS) except for EPS

Sr. No.	PARTICULARS	STANDALONE					
		QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	Total income from operations (Net)	7,818.28	6,097.92	5,567.92	13,916.20	10,289.78	21,160.05
2	Net Profit for the period (before tax,exceptional and/or extraordinary items)	1,512.60	1,273.42	921.86	2,786.02	1,733.07	3,817.45
3	Net Profit for the period before tax (after exceptional and/or extraordinary	1,512.60	1,273.42	921.86	2,786.02	1,733.07	3,817.45
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	1,133.07	945.59	686.25	2,078.66	1,302.33	2,744.72
5	Total comprehensive income for the period (comprising Profit for the period (after tax) and other comprehensive income(after tax)(refer note 3)	1,130.79	943.31	688.07	2,074.10	1,305.98	2,736.07
6	Paid-up equity share capital (Face value of Rs. 2/- per share)	826.37	826.37	826.37	826.37	826.37	826.37
7	Other equity excluding revaluation reserves as per the balance sheet	-	-	-	-	-	16,257.78
8	Earnings per share (of INR 2/- each)						
	(a) Basic	2.74	2.29	8.30	5.03	15.76	6.64
	(b) Diluted	2.74	2.29	8.30	5.03	15.76	6.64

NOTES :

1. The above is an extract of the detailed format of unaudited standalone financial results for the quarter and six months ended on 30.09.2026 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited Standalone Financial Results for the said quarter and six months ended on 30.09.2026 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
2. The above unaudited standalone financial results for the quarter and six months ended on 30.09.2026 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on November 05, 2026.The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirments), 2015.The results for the quarter and six months ended on 30th Sept. 2026, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)
3. The unaudited standalone financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
4. Freight amount has been added in revenue from operations for the purpose of calculation of sales excluding GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director
DIN-00027448

Place : Delhi
Dated : 05.11.2026

TITAN BIOTECH LIMITED

Standalone Balance Sheet as at 30th September, 2026

(Rs. in Lakhs.)

Particulars	As at	
	30/09/2026 Unaudited	31/03/2026 Audited
I. ASSETS		
1. Non-Current Assets		
a. Property, Plant and Equipment	5,259.92	5,133.97
b. Capital Work-in-Progress	514.91	172.73
c. Right of use Assets	976.80	1,018.48
d. Intangible assets	7.35	8.39
e. Intangible assets under development	-	-
f. Financial Assets		
(i) Investments	5,043.69	4,965.67
(ii) Other Financial Assets	480.58	483.01
g. Other non-current assets	11.39	11.38
Total Non-current assets	**12,294.64**	**11,793.63**
2. Current Assets		
a. Inventories	6,356.06	5,576.91
b. Financial Assets	-	
(i) Trade receivables	2,715.63	2,282.86
(ii) Cash and cash equivalents	433.55	147.77
(iii) Bank balances other than (ii) above	39.35	39.56
c. Current Tax Assets (Net)	-	-
d. Other Current Assets	1,381.33	477.15
Total Current assets	**10,925.92**	**8,524.25**
TOTAL ASSETS	**23,220.56**	**20,317.88**
II. EQUITY AND LIABILITIES		
A Equity		
a. Equity Share Capital	826.37	826.37
b. Other Equity	18,125.30	16,257.78
TOTAL EQUITY	**18,951.67**	**17,084.15**
B Liabilities		
1. Non-Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	36.63	32.67
(ii) Lease liabilities	139.93	144.33
b. Provisions	272.33	227.90
c. Deferred tax liabilities (Net)	236.81	232.56
Total Non-Current Liabilities	**685.70**	**637.46**
2. Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	384.15	334.40
(ii) Lease liabilities	34.22	59.32
(iii) Trade payables		
(a) Total outstanding dues of micro enterprise and small enterprises	601.94	215.11
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	522.63	638.99
(iv) Other financial liabilities	410.74	437.49
b. Other current liabilities	1,236.01	697.48
c. Provisions	86.87	86.87
d. Current Tax Liabilities (Net)	306.63	126.61
Total Current Liabilities	**3,583.19**	**2,596.27**
TOTAL EQUITY AND LIABILITIES	**23,220.56**	**20,317.88**

For Titan Biotech Limited

TITAN BIOTECH LIMITED

[Naresh Kumar Singla]
Managing Director
DIN-00027448

Place : Delhi
Dated : 05.11.2026

TITAN BIOTECH LIMITED

Standalone Cash Flow Statement for the period ended on 30th Sept, 2026

(Rs. in Lakhs.)

Particulars	Six months ended 30/09/2026 Unaudited	Six months ended 30/09/2025 Unaudited
A. CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before Tax	2,786.02	1,733.07
Adjustment for :	-	
Finance Costs	47.85	41.93
Provision for employee benefits	38.33	20.09
Earlier year Taxes	(0.02)	
Unrealised foreign exchange differences	14.64	(22.62)
Provision for expected credit losses of trade receivables	-	-
Depreciation and Amortization Expenses	269.19	236.15
Operating profit before working capital changes	3,156.01	2,008.62
Changes in working Capital:		
(Increase) in Inventories	(779.15)	510.37
(Increase)/ Decrease in trade receivables	(447.17)	(1,056.63)
(Increase)/ Decrease in other financial assets	2.42	(73.88)
(Increase)/ Decrease in other current assets	(904.17)	(707.15)
Increase/ (Decrease) in trade payables	270.23	85.83
Increase/ (Decrease) in other financial liabilities	(26.74)	345.78
Increase/ (Decrease) in other current liabilities	538.53	278.69
Cash generation from operation	1,809.96	1,391.63
Less: Income tax paid	(521.53)	(285.93)
Net Cash generated/ (used) - Operating Activities	1,288.43	1,105.69
B. CASH FLOWS FROM INVESTMENT ACTIVITIES		
Investments in debt instruments quoted and unquoted equity instruments	(78.02)	(1,349.79)
Purchase of property, plant and equipment	(366.82)	(135.80)
Proceeds from sale of property, plant & equipment	9.60	-
Addition of capital work in progress (net)	(342.18)	(182.20)
(Addition) in right of use assets	4.80	(31.99)
Proceeds from/(investment in) bank deposits	0.20	(153.58)
Net Cash Generated/ (Used) - Investing Activities	(772.42)	(1,853.36)
C.CASH FLOWS FROM FINANCING ACTIVITIES		
Repayment of Long-term Borrowings	3.95	6.34
Repayment of Lease Liabilities	(29.49)	6.63
Proceeds/(Repayment) of Short-term Borrowings (Net)	49.75	592.38
Finance Cost paid	(47.85)	(41.93)
Dividend paid	(206.59)	(165.27)
Net cash (used) - financing activities	(230.23)	398.15
Net (Decrease) in Cash and Cash Equivalents	285.78	(349.52)
Cash and cash equivalents at the beginning of the year	147.77	512.79
Cash and cash equivalents at the end of the year	**433.55**	**163.27**
Balance with banks	430.36	155.79
Cash on hand	3.19	7.48
Bank deposits with original maturity less than 3 months	-	-
Cash and cash equivalents as per Standalone Statement of Cash Flows	**433.55**	**163.27**

Notes:

1. The above Standalone Statement of Cash Flows has been prepared under the 'Indirect Method' as set out in Ind AS 7, 'Statement of Cash Flows'.
2. Figures in bracket represent outflows.
3. Previous year's figures have been regrouped wherever considered necessary to conform to this year's classification.

For Titan Biotech Limited

[Naresh Kumar Singla]
Managing Director
DIN-00027448

TITAN BIOTECH LIMITED

Place : Delhi
Dated : 05.11.2026

ANSK & ASSOCIATES
CHARTERED ACCOUNTANTS
Office : 705, B-08, GDITL Tower, Netaji Subhash Place Pitampura, New Delhi - 110034
Tel : 011-46010089

Independent Auditor's Review Report on Quarterly and Year to date Unaudited Consolidated Financial Results of Titan Biotech Limited Pursuant to the Regulations 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

THE BOARD OF DIRECTORS
TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Titan Biotech Limited (the "Company") and its Associates, for the quarter ended September 30, 2026, being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulations 33 and 52 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain

moderate assurance to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. The Statement includes results of the Holding Company - Titan Biotech Limited and Associate Company - Peptech Biosciences Limited and Titan Media Limited.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The unaudited consolidated financial results also includes the Associates's share of net profit after tax of Rs. 121.66 lacs and total comprehensive income of Rs. 121.62 Lacs for the Quarter ended 30th September 2026, as considered in the consolidated unaudited financial results, in respect of its Associates, based on their interim financial results of

M/s Peptech biosciences Limited and M/s Titan Media Limited which have been reviewed by our Audit Firm. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of its associates, are based solely on such unaudited interim financial results.

Our conclusion is not modified in respect of this matter.

For A N S K & Associates
Chartered Accountants
Firm's Registration No. 026177N

KAPIL SINGHAL
Digitally signed by KAPIL SINGHAL
Date: 2026.11.05 15:07:20 +05'30'

(CA Kapil Singal)
Partner
M.No. 520205
Date: November 05, 2026
Place: New Delhi
UDIN: 26520205ZCAJJB3445

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED ON 30TH SEPTEMBER, 2026

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	CONSOLIDATED					
		QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	**INCOME**						
	Revenue from operations	7,646.25	5,916.66	5,435.47	13,562.91	10,085.11	20,619.03
	Other income	172.03	181.26	132.45	353.29	204.67	541.02
	Total income	**7,818.28**	**6,097.92**	**5,567.92**	**13,916.20**	**10,289.78**	**21,160.05**
2	**EXPENSES**						
	Cost of materials consumed	3,951.09	2,992.80	2,742.73	6,943.89	4,598.01	9,916.35
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	41.12	(203.91)	(137.86)	(162.79)	401.81	(296.82)
	Employee benefits expense	966.70	869.68	738.26	1,836.38	1,439.58	3,236.20
	Finance costs	27.97	19.88	22.41	47.85	41.93	91.39
	Depreciation and amortization expense	132.50	136.69	120.95	269.19	236.15	492.53
	Other expenses	1,186.30	1,009.36	1,159.57	2,195.66	1,839.23	3,902.95
	Total expenses	6,305.68	**4,824.50**	4,646.06	**11,130.18**	**8,556.71**	17,342.60
3	**Profit before exceptional items and tax (1-2)**	**1,512.60**	**1,273.42**	**921.86**	**2,786.02**	**1,733.07**	**3,817.45**
4	Exceptional items	-	-	-	-	-	-
5	Profit before tax (3+4)	1,512.60	1,273.42	921.86	2,786.02	1,733.07	3,817.45
6	Tax expense						
	(I) Current tax	379.76	321.79	231.55	701.55	423.83	988.74
	(II) Deferred tax	(0.30)	6.04	4.06	5.74	6.91	83.99
	(III) Earlier year taxes	0.02	-	-	0.02	-	-
	Total tax (I+II+III)	379.48	327.83	235.61	707.31	430.74	1,072.73
7	Profit for the period (5-6)	**1,133.12**	**945.59**	**686.25**	**2,078.71**	**1,302.33**	**2,744.72**
8	Share in profit of associate	**121.66**	**140.09**	**90.22**	**261.75**	**160.42**	**243.80**
9	Profit for the period (7+8)	1,254.78	1,085.68	**776.47**	2,340.46	**1,462.75**	**2,988.52**
10	**Other comprehensive income**						
A	(i) Items that will not be reclasssified to profit or loss						
	(ia) Re-measurement gain on defined benefit plans	(3.04)	(3.05)	2.44	(6.09)	4.88	(12.19)
	(ii) Income tax on the above item	0.82	0.77	(0.62)	1.59	(1.23)	3.54
B	(i) Items that will be reclasssified to profit or loss			-		-	-
	(ii) Income tax on the above item			-		-	-
	Share in other comprehensive income of associate	(0.04)	(0.04)		(0.08)		(0.17)
	Total other comprehensive income for the period (A+B) (net of taxes)	**(2.26)**	**(2.32)**	**1.82**	**(4.58)**	**3.65**	**(8.82)**
11	**Total comprehensive income for the period (7+8)**	**1,252.52**	**1,083.36**	**778.29**	**2,335.88**	**1,466.40**	**2,979.70**
12	**Net profit attributable to:**						
	Owners of the holding company						
	Non-controlling interest						
13	**Other comprehensive income attributable to :**						
	Owners of the holding company						
	Non-controlling interest						
14	**Total comprehensive income attributable to (10+11)**						
	Owners of the holding company						
	Non-controlling interest						
15	Paid-up equity share capital (face value of Rs 2/- each)	826.37	826.37	826.37	826.37	826.37	826.37
16	Other Equity						17,328.38
17	Earnings per equity share (face value of Rs 2/- each) not annualised						
	(1) Basic	3.04	2.63	9.40	5.66	17.70	7.23
	(2) Diluted	3.04	2.63	9.40	5.66	17.70	7.23

Notes:

1 The above unaudited consolidated financial results for the quarter and six months ended on 30.09.2026 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on November 05, 2026. The statutory auditors of the company have carried out a limited review of the aforesaid results. The results for the quarter and six months ended Sept. 30, 2026, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)

2 The unaudited consolidated financial results for the quarter ended on 30.09.2026 include the results of following -
Associate Companies - Peptech Biosciences Limited and Titan Media Limited

3 Previous period figures are regrouped/reclassified in line with the current period

4 The Company has only one reportable business segment.

5 The unaudited consolidated financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").

6 Freight amount has been added in revenue from operations for the purpose of calculation of sales excluding GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Director
for TITAN BIOTECH LIMITED

TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director
DIN-00027448

Place : Delhi
Dated : 05.11.2026

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED ON 30TH SEPTEMBER, 2026

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	CONSOLIDATED					
		QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	Total income from operations (Net)	7,818.28	6,097.92	5,567.92	13,916.20	10,289.78	21,160.05
2	Net Profit for the period (before tax,exceptional and/or extraordinary items)	1,512.60	1,273.42	921.86	2,786.02	1,733.07	3,817.45
3	Net profit for the period before tax (after exceptional and/or extraordinary items)	1,512.60	1,273.42	921.86	2,786.02	1,733.07	3,817.45
4	Net profit for the period after tax (after exceptional and/or extraordinary items)	1,254.78	1,085.68	776.47	2,340.46	1,462.75	2,988.52
5	Total comprehensive income for the period (comprising Profit for the period(after tax) and other comprehensive income(after tax)(refer note 3)	1,252.52	1,083.36	778.29	2,335.88	1,466.40	2,979.70
6	Paid-up equity share capital (face value of Rs 2/- per share)	826.37	826.37	826.37	826.37	826.37	826.37
7	Other equity excluding revaluation reserves as per the balance sheet	-	-	-	-	-	17,328.38
8	Earnings per share (of INR 2/- each)						
	(a) Basic	3.04	2.63	9.40	5.66	17.70	7.23
	(b) Diluted	3.04	2.63	9.40	5.66	17.70	7.23

NOTES :

1. The above is an extract of the detailed format of unaudited consolidated financial results for the quarter and six months ended on 30.09.2026 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited consolidated financial results for the said quarter and six months ended on 30th Sept 2026 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com
2. The above unaudited consolidated financial results for the quarter and six months ended on 30.09.2026 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on November 05, 2026. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
3. The unaudited consolidated financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India")
4. Freight amount has been added in revenue from operations for the purpose of calculation of sales excluding GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director
DIN-00027448

Place : Delhi
Dated : 05.11.2026

TITAN BIOTECH LIMITED

Consolidated Balance Sheet as at 30th September, 2026

(Rs. in Lakhs.)

Particulars	As at	
	30/09/2026 Unaudited	31/03/2026 Audited
I ASSETS		
1. Non-Current Assets		
a. Property, Plant and Equipment	5,259.92	5,133.97
b. Capital Work-in-Progress	514.91	172.73
c. Right of use Assets	976.80	1,018.48
d. Intangible assets	7.35	8.39
e. Intangible assets under development	-	-
f. Financial Assets		
(i) Investments	6,375.96	6,036.27
(i) Other Financial Assets	480.58	483.01
g. Other non-current assets	11.39	11.38
Total Non-current assets	**13,626.91**	**12,864.23**
2. Current Assets		
a. Inventories	6,356.06	5,576.91
b. Financial Assets		
(i) Trade receivables	2,715.63	2,282.86
(ii) Cash and cash equivalents	433.55	147.77
(iii) Bank balances other than (ii) above	39.35	39.56
c. Current Tax Assets (Net)	-	-
d. Other Current Assets	1,381.33	477.15
Total Current assets	**10,925.92**	**8,524.25**
TOTAL ASSETS	**24,552.83**	**21,388.48**
II. EQUITY AND LIABILITIES		
A Equity		
a. Equity Share Capital	826.37	826.37
b. Other Equity	19,457.68	17,328.38
TOTAL EQUITY	**20,284.05**	**18,154.75**
B Liabilities		
1. Non-Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	36.63	32.67
(ii) Lease liabilities	139.93	144.33
c. Provisions	272.33	227.90
b. Deferred tax liabilities (Net)	236.70	232.56
Total Non-Current Liabilities	**685.59**	**637.46**
2. Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	384.15	334.40
(ii) Lease liabilities	34.22	59.32
(iii) Trade payables		
(a) Total outstanding dues of micro enterprise and small enterprises	601.94	215.11
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	522.63	638.99
(iv) Other Financial Liabilities	410.74	437.49
b. Other current liabilities	1,236.01	697.48
c. Provisions	86.87	86.87
d. Current Tax Liabilities (Net)	306.63	126.61
Total Current Liabilities	**3,583.19**	**2,596.27**
TOTAL EQUITY AND LIABILITIES	**24,552.83**	**21,388.48**

For Titan Biotech Limited

[Naresh Kumar Singla]
Managing Director
DIN-00027448

TITAN BIOTECH LIMITED

Place : Delhi
Dated : 05.11.2026

TITAN BIOTECH LIMITED

Consolidated Cash Flow Statement for the period ended on 30th September, 2026

(Rs. in Lakhs.)

Particulars	Six months ended 30/09/2026 Unaudited	Six months ended 30/09/2025 Audited
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before Tax	**2,786.02**	**1,733.07**
Adjustment for :		
Finance Costs	47.85	41.93
Provision for employee benefits	38.33	20.09
Earlier year Taxes	(0.02)	-
Unrealised foreign exchange differences	14.64	(22.62)
Provision for expected credit losses of trade receivables	-	-
Depreciation and Amortization Expenses	269.19	236.15
Operating profit before working capital changes	3,156.01	2,008.62
Changes in working Capital:		
(Increase) in Inventories	(779.15)	510.37
(Increase)/ Decrease in trade receivables	(447.17)	(1,056.63)
(Increase)/ Decrease in other financial assets	2.42	(73.88)
(Increase)/ Decrease in other current assets	(904.17)	(707.15)
Increase/ (Decrease) in trade payables	270.23	85.83
Increase/ (Decrease) in other financial liabilities	(26.74)	345.78
Increase/ (Decrease) in other current liabilities	538.53	278.69
Cash generation from Operation	1,809.96	1,391.63
Payment of Direct Taxes	(521.53)	(285.93)
Net Cash generated/ (used) - Operating Activities	1,288.43	1,105.69
B. CASH FLOW FROM INVESTMENT ACTIVITIES		
Investments in debt instruments quoted and unquoted equity instruments	(78.02)	(1,349.79)
Purchase of property, plant and equipment	(366.82)	(135.80)
Proceeds from sale of property, plant & equipment	9.60	-
Addition of capital work in progress (net)	(342.18)	(182.20)
(Addition) in right of use assets	4.80	(31.99)
Proceeds from/(investment in) bank deposits	0.20	(153.58)
Net Cash Generated/ (Used) - Investing Activities	(772.42)	(1,853.36)
C.CASH FLOW FROM FINANCING ACTIVITIES		
Repayment of Long-term Borrowings	3.95	6.34
Repayment of Lease Liabilities	(29.49)	6.63
Proceeds/(Rapyment)of Short-term Borrowings(Net)	49.75	592.38
Finance Cost paid	(47.85)	(41.93)
Dividend paid	(206.59)	(165.27)
Net cash (used) - financing activities	(230.23)	398.15
Net (Decrease) in Cash and Cash Equivalents	285.78	(349.52)
Cash and cash equivalents at the beginning of the year	147.77	512.79
Cash and cash equivalents at the end of the year	**433.55**	**163.27**
Balance with banks	430.36	155.79
Cash on hand	3.19	7.48
Bank deposits with original maturity less than 3 months	-	-
Cash and cash equivalents as per Standalone Statement of Cash Flows	**433.55**	**163.27**

Notes:

1. The above Consolidated Statement of Cash Flows has been prepared under the 'Indirect Method' as set out in Ind AS 7, 'Statement of Cash Flows'.
2. Figures in bracket represent outflows.
3. Previous year's figures have been regrouped wherever considered necessary to conform to this year's classification.

For Titan Biotech Limited

TITAN BIOTECH LIMITED

[Naresh Kumar Singla]
Managing Director
DIN-00027448

Place : Delhi
Dated : 05.11.2026